May 11, 2020 News by Joana Carvalho, PhD MMJ Can Ship Cannabis Products to US for Clinical Testing, Agencies Say MMJ International HoldingsĀ announced that it has been given clearance to ship its cannabis-based products to the U.S. for use in future clinical trials of potential cannabis-based treatment forĀ multiple sclerosis (MS) and Huntingtonās disease. The process was…
March 31, 2020 News by Marisa Wexler, MS Canada Rules EHP-101, Potential Cannabidiol Treatment, Not Controlled Substance EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health PharmaceuticalsĀ (EHP)Ā to treat multiple sclerosis (MS), is not a controlled substance in Canada, the company announced. The active ingredient in EHP-101 is a derivative of cannabidiol, abbreviated…
March 18, 2020 News by David Melamed, PhD MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports About 85% of people with multiple sclerosis (MS) usingĀ cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people…
March 12, 2020 News by Forest Ray PhD THC:CBD Oral Spray Sativex Provides Consistent Relief for Treatment-resistant MS Spasticity Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticityĀ in multiple sclerosis (MS) patients, according to a recent study. An analysis of theĀ Sativex as Add-on therapy…
March 3, 2020 News by Marta Figueiredo, PhD #ACTRIMS2020 – EHP-101 Shows Promise in Early Studies; Phase 2 Trial Ahead Emerald Health Pharmaceuticalsā investigational cannabidiol-derived EHP-101 continues to show potential to ease inflammation and myelin loss (demyelination) ā a hallmark of multiple sclerosis (MS) ā according to data from healthy volunteers and a mouse model of…
December 9, 2019 News by Marisa Wexler, MS Atlas Biotechnologies to Fund Research into Cannabis Treatment for MS, Similar Diseases Atlas BiotechnologiesĀ will fund and provide support to three research projects at the University of AlbertaĀ to possibly identify cannabis component(s) that could help people with neurological diseases likeĀ multiple sclerosis (MS). The cannabis plant produces hundreds of biological…
November 25, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Immunoadsorption, MS Therapies Approval, Cannabis-based Capsules for Study, Pregnancy and MS Immunoadsorption May Be Superior to Plasma Exchange in Treating Steroid-resistant Relapses in MS Steroids may be an effective treatment for multiple sclerosis relapses, but they have negative side effects. Many people report a metallic taste, while others…
November 20, 2019 News by Alice MelĆ£o, MSc MMJ Enters Agreement to Produce Cannabis-based Capsules for Clinical Trials in MS and Huntingtonās MMJ International HoldingsĀ announced that it has entered into an agreement for the production of its proprietary cannabis-based gel capsule ā a product mix of tetrahydrocannabinol (THC) and cannabidiol (CBD) ā in compliance with guidelines set by the U.S.
November 13, 2019 News by Mary Chapman Sativex, Cannabis Extract for MS Spasticity, Now Available to Select Patients in England The cannabis sativa plant extract SativexĀ is a cost-effective therapy for spasticity in multiple sclerosis (MS) and can be offered to patients in England needing it on at least a monthlong trial basis, the National Institute…
October 31, 2019 News by Ana Pena PhD Medicinal Cannabinoids Not Effective for Mental Disorders, Small Relief on MS Anxiety, Analysis Suggests A joint analysis of 83 studies, involving 3,000 people, concluded that there is “scarce evidence” to say that the use of medicinal cannabinoids ā chemical compounds in the cannabis plant ā is able to improve mental health conditions.